The Scholz Group
Dr. Hanne Scholz is senior scientist at the Department of Transplantation Medicine at the Oslo University Hospital (OUS), and the director of the human islet isolation facility producing clinical approved pancreatic insulin-producing for treatment of type 1 diabetes in Norway. Scholz is the project leader of “Oslo Regenerative Medicine Initiative”, a focus research area appointed by OUS. The Scholz research group is devoted to improving and optimizing islet isolation, transplantation and clinical outcome of beta cell replacement therapy. A recent research focus is developing a stem cell based cellular therapy for diabetes and developing a functional mini-pancreas for the "organ on a chip" platform.
- Abadpour S, Halvorsen B, Sahraoui A, Korsgren O, Aukrust P, Scholz H (2018) Interleukin-22 reverses human islet dysfunction and apoptosis triggered by hyperglycemia and LIGHT J Mol Endocrinol (in press) PubMed 29330151
- Schuetz C, Anazawa T, Cross SE, Labriola L, Meier RPH, Redfield RR, Scholz H, Stock PG, Zammit NW, IPITA YIC Young Investigator Committee (2018) β Cell Replacement Therapy: The Next 10 Years Transplantation, 102 (2), 215-229 PubMed 28885496
- Abadpour S, Göpel SO, Schive SW, Korsgren O, Foss A, Scholz H (2017) Glial cell-line derived neurotrophic factor protects human islets from nutrient deprivation and endoplasmic reticulum stress induced apoptosis Sci Rep, 7 (1), 1575 PubMed 28484241
- Schive SW, Mirlashari MR, Hasvold G, Wang M, Josefsen D, Gullestad HP, Korsgren O, Foss A, Kvalheim G, Scholz H (2017) Human Adipose-Derived Mesenchymal Stem Cells Respond to Short-Term Hypoxia by Secreting Factors Beneficial for Human Islets In Vitro and Potentiate Antidiabetic Effect In Vivo Cell Med, 9 (3), 103-116 PubMed 28713640
- Vethe H, Bjørlykke Y, Ghila LM, Paulo JA, Scholz H, Gygi SP, Chera S, Ræder H (2017) Probing the missing mature β-cell proteomic landscape in differentiating patient iPSC-derived cells Sci Rep, 7 (1), 4780 PubMed 28684784